Targets › PSMB5
20 programs from 20 companies in 117 trials: 68 Phase 2, 29 Phase 1, 16 Phase 3, 4 Phase 4; Oncology, Metabolic and endocrine, Neurology; next expected readout Dec 2026.
Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. (UniProt, P28074)
Open in Phaseline: the race on PSMB5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 4 | Multiple Myeloma | Jul 2028 |
| University of Leeds | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 3 | Multiple Myeloma | Mar 2027 |
| University of Arkansas | Bortezomib D-Mannitol 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 3 | Multiple Myeloma; Myeloma | Aug 2027 |
| Regeneron Pharmaceuticals | Carfilzomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | May 2029 |
| Alliance Foundation Trials, LLC. | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Myeloma, Multiple | Dec 2026 |
| Washington University School of Medicine | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Multiple Myeloma | Aug 2027 |
| Tel-Aviv Sourasky Medical Center | ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Multiple Myeloma in Relapse | Sep 2027 |
| European Myeloma Network B.V. | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Multiple Myeloma | Sep 2027 |
| M.D. Anderson Cancer Center | Ixazomib Citrate 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Recurrent Plasma Cell Myeloma; Metastatic Urothelial Carcinoma | Oct 2027 |
| Raija Silvennoinen | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Multiple Myeloma | Dec 2027 |
| University of Washington | Ixazomib Citrate 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Chronic Lymphocytic Leukemia | Jan 2028 |
| Karyopharm Therapeutics | Bortezomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Multiple Myeloma, Refractory; Hematological Neoplasms; Newly Diagnosed; Multiple Myeloma … | Jan 2028 |
| AIDS Malignancy Consortium | Ixazomib Citrate 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Kaposi Sarcoma | Mar 2029 |
| Nantes University Hospital | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | Multiple Myeloma at First Relapse | Jan 2030 |
| Memorial Sloan Kettering Cancer Center | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 2 | AL Amyloidosis | – |
| Omar Nadeem, MD | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 1 | Multiple Myeloma | Jan 2027 |
| Queen Mary University of London | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 1 | Relapsing Remitting Multiple Sclerosis | Jul 2027 |
| Pfizer | Carfilzomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 1 | Multiple Myeloma; Newly Diagnosed; Plasma Cell Myeloma; Newly Diagnosed Multiple Myeloma … | Feb 2028 |
| National Cancer Institute (NCI) | Ixazomib Citrate 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 1 | Recurrent AL Amyloidosis | Jun 2028 |
| Therapeutic Advances in Childhood Leukemia Consortium | Ixazomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 1 | ALL, Childhood | – |
Multiple Myeloma (35) Plasma Cell Myeloma (5) Recurrent Plasma Cell Myeloma (5) Myeloma (3) Plasma Cell Leukemia (3) Newly Diagnosed (2) Newly Diagnosed Multiple Myeloma (2) Multiple Myeloma in Relapse (2) Recurrent Multiple Myeloma (2) Smoldering Multiple Myeloma (2) Waldenstrom Macroglobulinemia (2) Refractory Multiple Myeloma (2)
small molecule (10), mixed (9)
University of Arkansas (1) National Cancer Institute (NCI) (1) Pfizer (1) AIDS Malignancy Consortium (1) University of Leeds (1) University of Washington (1) Queen Mary University of London (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Nantes University Hospital (1) Raija Silvennoinen (1) Karyopharm Therapeutics (1) Omar Nadeem, MD (1) European Myeloma Network B.V. (1) Memorial Sloan Kettering Cancer Center (1) M.D. Anderson Cancer Center (1) Tel-Aviv Sourasky Medical Center (1) Alliance Foundation Trials, LLC. (1) Regeneron Pharmaceuticals (1) Therapeutic Advances in Childhood Leukemia Consortium (1) Washington University School of Medicine (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.